CG Oncology (CGON) Q3 2025 Financial Results Summary
QuoteReporter
CG Oncology (CGON) Q3 2025 Financial Results Summary
On November 14, 2025, CG Oncology, Inc. (NASDAQ: CGON) released its financial results for the third quarter ending September 30, 2025, alongside significant business updates.
Financial Highlights
- Cash Position:
- Cash and cash equivalents, along with marketable securities, totaled $680.3 million as of September 30, 2025, an increase of 2.7% from $661.1 million on June 30, 2025.
-
Approximately $48.7 million net proceeds from the sale of 1,515,151 shares were raised through the Company’s at-the-market facility.
-
Research and Development (R&D) Expenses:
-
R&D expenses for Q3 2025 were $27.9 million, a rise of 42.4% compared to $19.6 million for the same quarter in 2024.
-
General and Administrative (G&A) Expenses:
-
G&A expenses reached $23.3 million in Q3 2025, compared to $8.7 million in Q3 2024, reflecting a significant increase of 168.4%.
-
Net Loss:
- The net loss for the third quarter was $43.8 million, or ($0.57) per share, which is a 114% increase from a net loss of $20.4 million or ($0.30) per share in Q3 2024.
Revenue Summary
- Total Revenues:
- Revenues for Q3 2025 were $1.67 million, a substantial increase from $43,000 in Q3 2024.
- The revenue included $1.51 million from commercial and development activities and $158,000 from license and collaboration agreements, compared to $43,000 last year.
Operational Insights
- Cretostimogene Highlights:
- Biologics License Application (BLA): The company has initiated a rolling BLA submission to the U.S. FDA for cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
- Best-in-Disease Data: Presenting data from BOND-003 Cohort C, CG Oncology reported a 41.8% complete response rate at 24 months in patients treated with cretostimogene, maintaining 90% of 12-month responders being disease-free.
- Enrollment Completion: The company successfully completed enrollment in the PIVOT-006 study approximately 10 months ahead of schedule, demonstrating robust interest from patients and physicians.
Future Outlook
- CG Oncology anticipates several key milestones in the coming quarters:
- Release of topline data from the BOND-003 Cohort P in Q4 2025.
- Initial results from the CORE-008 Cohort A in Q4 2025.
- Completion of the BLA submission expected by 2026.
Share Repurchase & Dividends
- The company did not declare any quarterly dividends or announce any share repurchase plans during this reporting period.
Summary Table of Key Metrics
| Metric | Q3 2025 | Q3 2024 | Change (%) |
|---|---|---|---|
| Cash & Cash Equivalents | $680.3 million | $661.1 million | +2.7% |
| R&D Expenses | $27.9 million | $19.6 million | +42.4% |
| G&A Expenses | $23.3 million | $8.7 million | +168.4% |
| Net Loss | $43.8 million | $20.4 million | +114% |
| Total Revenues | $1.67 million | $43,000 | +~3,870% |
CG Oncology continues to advance its clinical programs while managing its operational expenditures, positioning itself for potential growth paths as it progresses through regulatory submissions and clinical trials. The financial results reflect not only a commitment to innovation in the field of bladder cancer therapeutics but also the challenges associated with high development costs.
Here are the extracted tables in Markdown format:
CG ONCOLOGY, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (unaudited)
| Three Months Ended September 30, 2025 | Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 | |
|---|---|---|---|---|
| Revenues | $1,508 | $— | $1,508 | $— |
| License and collaboration revenue | 158 | 43 | 210 | 683 |
| Total revenues | 1,666 | 43 | 1,718 | 683 |
| Operating costs and expenses | ||||
| Cost of sales | 1,577 | — | 1,577 | — |
| Research and development | 27,884 | 19,622 | 86,683 | 55,302 |
| General and administrative | 23,334 | 8,716 | 55,532 | 21,998 |
| Total operating costs and expenses | 52,795 | 28,338 | 143,792 | 77,300 |
| Loss from operations | (51,129) | (28,295) | (142,074) | (76,617) |
| Other income (expense), net: | ||||
| Interest income, net | 7,421 | 7,892 | 22,487 | 20,379 |
| Other (expense) income, net | (100) | (2) | (99) | (3) |
| Total other income, net | 7,321 | 7,890 | 22,388 | 20,376 |
| Net loss and comprehensive loss | (43,808) | (20,405) | (119,686) | (56,241) |
| Net loss per share, basic and diluted | (0.57) | (0.30) | (1.57) | (0.93) |
| Weighted average shares of common stock outstanding, basic and diluted | 76,729,726 | 67,143,744 | 76,383,376 | 60,311,003 |
CG ONCOLOGY, INC. Consolidated Balance Sheet Data (In thousands)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Cash, cash equivalents, and marketable securities | $680,263 | $741,998 |
| Total assets | 729,913 | 754,797 |
| Total liabilities | 42,270 | 21,420 |
| Total stockholders’ equity | 687,643 | 733,377 |